)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Avinger
Avinger (AVGR) investor relations material
Avinger has been delisted
Avinger Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary7 Nov, 2024
Executive summary
Q3 2024 revenue ranged from $1.65 million to $1.7 million, with gross margin improving to 26% from 21% in Q3 2023 and net loss at $3.7 million, reflecting cost reduction measures including a 24% workforce reduction and sales realignment.
Operating efficiency improved, with a 15% reduction in net loss and 12% improvement in adjusted EBITDA compared to Q2 2024.
Pantheris LV launched commercially with strong early feedback, and the coronary CTO system advanced toward FDA submission, with IDE filing anticipated in Q4 2024 and patient enrollment expected in H1 2025.
Partnership with Zylox-Tonbridge advanced for China market entry, manufacturing, and regulatory progress, with regulatory approval anticipated in the second half of 2025.
Substantial doubt exists about the ability to continue as a going concern without additional financing, as cash is expected to fund operations only through Q4 2024.
Financial highlights
Q3 2024 revenue was $1.65–$1.7 million, down from $1.8 million in Q2 2024 and Q3 2023; nine-month revenue was $5.36 million, down 7% year-over-year.
Gross margin improved to 26% in Q3 2024 from 20% in Q2 2024 and 21% in Q3 2023; nine-month gross margin declined to 21% from 28% year-over-year.
Operating expenses declined to $4.1 million from $4.5 million in Q2 2024 and $4.4 million in Q3 2023.
Net loss was $3.7 million in Q3 2024, a 15% improvement from Q2 2024 and 17% from Q3 2023; nine-month net loss was $13.6 million.
Cash and cash equivalents totaled $5.9 million as of September 30, 2024, expected to fund operations only through Q4 2024.
Outlook and guidance
IDE application for the coronary CTO crossing system expected to be filed after FDA pre-submission feedback in Q4 2024, with patient enrollment targeted for H1 2025.
Regulatory approval for product entry into China anticipated in the second half of 2025, with manufacturing scale-up by Zylox-Tonbridge expected by mid-2025.
Cash on hand and expected revenues projected to fund operations only through Q4 2024; additional capital is needed to continue beyond this period.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Avinger
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Avinger Inc. is a medical device company that develops and manufactures innovative catheter-based technologies for the treatment of peripheral artery disease (PAD). The company’s core products are image-guided, minimally invasive devices designed to help physicians diagnose and treat arterial blockages in the lower extremities. Avinger's proprietary technology, including its optical coherence tomography (OCT) imaging, enables real-time visualization of the artery during procedures, improving precision and outcomes for patients. The company focuses on advancing solutions that reduce the need for more invasive surgical interventions. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.